Dabigatran versus Warfarin in Patients with Atrial Fibrillation.

Creative Commons License

Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.361, no.12, pp.1139-1151, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 361 Issue: 12
  • Publication Date: 2009
  • Doi Number: 10.1056/nejmoa0905561
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1139-1151
  • Ankara University Affiliated: No

Abstract

Background: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.